Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLAT: Tarlatamab + Platinum Rechallenge in Relapsed SCLC
NCT07699237Phase 2Not yet recruiting
- Sponsor
- University of Cologne
- Start
- Nov 2026
- Primary completion
- Jun 2031
01
Overview
Phase 2, open-label, single-arm trial of tarlatamab, carboplatin and etoposide in small cell lung cancer (SCLC), sponsored by University of Cologne. Primary endpoint: Progression-Free Survival up to 5 years. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
tarlatamabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07699237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07699237.